Skip to main content
Premium Trial:

Request an Annual Quote

William Van Nostrand, John Cassimatis, Alan Seadler, Thomas Petzinger Jr., Marc-Henri Galletti, Matthew McGinniss

Premium

William Van Nostrand and John Cassimatis were named vice presidents in the life sciences group of Long Beach, Calif.-based First Consulting Group. Van Nostrand, previously president of Dendrite’s clinical trials division in Morristown, NJ, becomes senior vice president of US sales; Cassimatis becomes VP of performance improvement.

 

Alan Seadler was named CEO of Crystalplex of Pittsburgh, effective May 1, succeeding Thomas Petzinger Jr., who will continue as chairman and CEO of LaunchCyte, which founded Crystalplex. Seadler previously was vice president of the executive corps program for the Pittsburgh Life Sciences Greenhouse. Crystalpex is preparing to commercialize labeled nanocrystal beads. Seadler holds a doctorate in biology from Case Western Reserve University.

 

Marc-Henri Galletti has joined Pequot Capital Management of New York as vice president of Pequot Ventures to focus on investments in biotechnology and medical devices. Previously, Galletti was a private equity research analyst at Amerindo Investment Advisors.

 

Matthew McGinniss has been named associate scientific director of molecular genetics for Quest Diagnostics Nichols Institute.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.